Literature DB >> 32476904

Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.

Andrew M Courtwright1,2, Bruno G Baldi3, Pranav Kidambi2, Ye Cui2, Anthony M Lamattina2, Julian A Villalba2, Shefali Bagwe2, Hilary J Goldberg2, Ivan O Rosas2, Elizabeth Petri Henske2, Carlos R R Carvalho3, Souheil El-Chemaly2.   

Abstract

Background: A subset of lymphangioleiomyomatosis (LAM) patients present with normal FEV1 and FVC but with reduced DLCO. Patients with an isolated reduction in DLCO in other diseases appear to be at higher risk for pulmonary hypertension and worse survival but this has not been previously described in LAM patients. Objective: To characterize the prevalence and clinical progression of LAM patients who present with discordantly low DLCO.
Methods: This was a retrospective cohort study of LAM patients in two centers in the United States and Brazil. Discordant DLCO was defined as FEV1 >80% predicted, FVC >80% predicted, and DLCO<80% predicted. We compared the rate of decline in pulmonary function, pulmonary artery to aorta (PA-A) ratio, and VEGF-D levels in patients with concordant and discordant DLCO.
Results: The overall prevalence of discordant DLCO was 26.0%. Patients with discordant DLCO did not have a higher rate of yearly decline in FEV1 (-1.0±0.6 vs -1.0±0.6, p=0.50), FVC (-1.0±0.7 vs -0.3±0.8, p=0.54), or DLCO (-2.2±0.9 vs -1.6±0.6, p=0.79). They did not have higher rates of PA-A ratio>1 (23.3% vs 20.1%, p=1.00). Patients with discordant DLCO did not have higher levels of VEGF-D (1214±1256 pg/mL vs 1706±1214 pg/mL, p=0.07). Conclusions: LAM patients who present with a discordantly low DLCO do not appear to have different rates of decline in pulmonary function. Additional biological and radiographic markers are needed to more fully characterize this population. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 206-212). Copyright:
© 2018.

Entities:  

Keywords:  DLCO; FEV1; VEGF; lymphangioleiomyomatosis; pulmonary artery to aorta ratio

Year:  2018        PMID: 32476904      PMCID: PMC7170150          DOI: 10.36141/svdld.v35i3.6321

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  26 in total

1.  The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors.

Authors:  Mie Hayashida; Kuniaki Seyama; Yoshikazu Inoue; Keisaku Fujimoto; Keishi Kubo
Journal:  Respirology       Date:  2007-07       Impact factor: 6.424

2.  Pulmonary vascular shunts in exercise-intolerant patients with lymphangioleiomyomatosis.

Authors:  Muhammad A Zafar; Francis X McCormack; Shahid Rahman; Christian Tencza; Kathryn A Wikenheiser-Brokamp; Lisa R Young; Yukitaka Shizukuda; Jean M Elwing
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Authors:  Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

5.  Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.

Authors:  Vincent Cottin; Sergio Harari; Marc Humbert; Hervé Mal; Peter Dorfmüller; Xavier Jaïs; Martine Reynaud-Gaubert; Grégoire Prevot; Romain Lazor; Camille Taillé; Jacques Lacronique; Sabrina Zeghmar; Gérald Simonneau; Jean-François Cordier
Journal:  Eur Respir J       Date:  2012-02-23       Impact factor: 16.671

6.  Pulmonary Vasculopathy Associated with FIGF Gene Mutation.

Authors:  Evan Bailey; Ye Cui; Alicia Casey; Joan M Stoler; Xingbin Ai; Dongdong Ma; Robert Handin; Piotr Sliz; Sara O Vargas; Souheil Y El-Chemaly
Journal:  Am J Pathol       Date:  2016-11-12       Impact factor: 4.307

7.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

8.  Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome.

Authors:  Beatriz L G Lima; Alex V C França; Antonio Pazin-Filho; Whemberton M Araújo; José A B Martinez; Benedito C Maciel; Marcus V Simões; João Terra-Filho; Ana L C Martinelli
Journal:  Mayo Clin Proc       Date:  2004-01       Impact factor: 7.616

9.  Pulmonary arterial involvement leading to alveolar hemorrhage in lymphangioleiomyomatosis.

Authors:  Bruno Guedes Baldi; Suzana Pinheiro Pimenta; Alexandre de Melo Kawassaki; Fabíola Del Carlo Bernardi; Marisa Dolhnikoff; Carlos Roberto Ribeiro Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 10.  Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD.

Authors:  J Michael Wells; Mark T Dransfield
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.